Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD
Exploring Mechanisms of Action of ±3,4-methylenedioxymethamphetamine (MDMA)- Assisted Psychotherapy for Posttraumatic Stress Disorder (PTSD)
Sponsor: Lykos Therapeutics
This observational or N/A phase trial investigates Posttraumatic Stress Disorder and is currently completed. Lykos Therapeutics leads this study, which shows 14 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Dec 2024 — Sep 2025 [monthly]
Completed
-
Sep 2024 — Dec 2024 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2024 — Jul 2024 [monthly]
Completed
▶ Show 9 earlier versions
-
Jan 2024 — Feb 2024 [monthly]
Completed
-
Aug 2023 — Jan 2024 [monthly]
Completed
-
Jul 2022 — Aug 2023 [monthly]
Completed
-
Oct 2021 — Jul 2022 [monthly]
Completed
Phase: PHASE2 → None
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lykos Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .